Article
Oncology
Carolina A. Ferreira, Pedram Heidari, Bahar Ataeinia, Nicoleta Sinevici, Meghan E. Sise, Robert B. Colvin, Eric Wehrenberg-Klee, Umar Mahmood
Summary: Cancer immunotherapy has greatly improved patient prognosis, but immune-related adverse events remain a challenge. This study demonstrates the use of a granzyme B-targeted PET imaging agent to identify and visualize such events in a murine model, providing potential clinical applications.
CLINICAL CANCER RESEARCH
(2021)
Review
Dermatology
Jingyao Liang, Sanquan Zhang, Qian Li, Yihui Yu, Xiaoyin Chen, Xibao Zhang
Summary: Although secukinumab has shown high efficacy and safety in psoriasis and psoriatic arthritis, it can lead to adverse events of special interest (AESI) such as inflammatory bowel disease, eczematous drug eruption, drug-associated vasculitis, and drug-induced lupus erythematosus. Most of these AESI are mild to moderate and resolve after discontinuation of secukinumab.
DERMATOLOGIC THERAPY
(2022)
Article
Oncology
Kohei Somekawa, Nobuyuki Horita, Ayami Kaneko, Yoichi Tagami, Nobuhiko Fukuda, Hiromi Matsumoto, Ho Namkoong, Yu Fujiwara, Kaoru Minegishi, Takeshi Fukumoto, Keisuke Watanabe, Yu Hara, Nobuaki Kobayashi, Takeshi Kaneko
Summary: This study found that the combination of nivolumab and ipilimumab (N3I1) induced fewer adverse events (AEs), grade 3 or higher AEs, and serious AEs compared to the alternative dosage combination (N1I3).
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Review
Medicine, General & Internal
Zeinab Mohseni Afshar, Ali Tavakoli Pirzaman, Jackson J. J. Liang, Akanksha Sharma, Marzieh Pirzadeh, Arefeh Babazadeh, Erfan Hashemi, Niloofar Deravi, Sadaf Abdi, Amirreza Allahgholipour, Rezvan Hosseinzadeh, Zahra Vaziri, Terence T. T. Sio, Mark J. M. Sullman, Mohammad Barary, Soheil Ebrahimpour
Summary: COVID-19 vaccines have been associated with both common side effects and rare adverse events that require further evaluation.
FRONTIERS IN MEDICINE
(2022)
Review
Public, Environmental & Occupational Health
Sara Soares, Vania Rocha, Michelle Kelly-Irving, Silvia Stringhini, Silvia Fraga
Summary: This systematic review provides evidence on the biological effects of adverse childhood events (ACEs) in children, showing associations between ACEs and immune system biomarkers, DNA methylation, and telomere length. These findings suggest that ACEs can lead to physiological changes that may contribute to the development of diseases later in life.
FRONTIERS IN PUBLIC HEALTH
(2021)
Review
Biochemical Research Methods
Chun Yen Lee, Yi-Ping Phoebe Chen
Summary: Traditional machine learning methods for detecting drug side effects are labor-intensive, while deep learning approaches, with the integration of heterogeneous drug data sources and innovative deployment, can help reduce adverse drug reactions and find replacements for drugs with side effects, as well as diversify drug utilization through drug repurposing.
BRIEFINGS IN BIOINFORMATICS
(2021)
Article
Biochemical Research Methods
Zhuohang Yu, Zengrui Wu, Weihua Li, Guixia Liu, Yun Tang
Summary: MetaADEDB is an online database used to integrate comprehensive information on adverse drug events. The second version collects new data from multiple sources and increases over 40% in drug-ADE associations. The new version also features a user-friendly web interface for data search and analysis.
Article
Oncology
LeAnne Young, Shanda Finnigan, Howard Streicher, Helen X. Chen, James Murray, H. Nida Sen, Elad Sharon
Summary: Ocular adverse events are rare complications of PD-1/PD-L1 inhibitor therapy, but can be severe enough to cause treatment discontinuation or delay. Proper evaluation by eye specialists is necessary in managing these adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Pharmacology & Pharmacy
Hayato Katsuno, Tomoya Tachi, Takuya Matsuyama, Mayuko Sugioka, Satoshi Aoyama, Tomohiro Osawa, Yoshihiro Noguchi, Masahiro Yasuda, Chitoshi Goto, Takashi Mizui, Hitomi Teramachi
Summary: In Japan, high medical costs are often caused by managing adverse drug events, and the costs of avoidable adverse drug events in older adults based on the BCJ and GMTSE-2015 account for a substantial proportion of the medical cost. By using the BCJ and GMTSE-2015, avoiding adverse drug events and reducing medical costs may be possible.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Oncology
Inigo Les, Mireia Martinez, Ines Perez-Francisco, Maria Cabero, Lucia Teijeira, Virginia Arrazubi, Nuria Torrego, Ana Campillo-Calatayud, Inaki Elejalde, Grazyna Kochan, David Escors
Summary: Immune-checkpoint inhibitors (ICIs) are widely used in cancer treatment, but they can cause immune-related adverse events (irAEs) in a significant number of patients. Predicting irAEs has become important for managing patients on ICIs. This review discusses biomarkers that have shown potential for predicting irAEs, including those already available for clinical use and those under investigation. Although these biomarkers have not been validated in prospective studies, there is growing evidence supporting their use for predicting and characterizing irAEs, which depend on factors such as the type of cancer, ICI agent, and affected organ. Further research is needed to understand the mechanisms of irAEs and to assess the predictive capacity of different biomarkers.
Editorial Material
Gastroenterology & Hepatology
Giulia Zudeh, Raffaella Franca, Gabriele Stocco, Giuliana Decorti
Summary: Thiopurines are effective immunomodulators in treating leukemia and bowel diseases, but adverse reactions can lead to treatment discontinuation. Myelosuppression and gastrointestinal toxicity are common adverse effects, and identifying biomarkers to prevent and monitor these reactions is crucial for clinicians managing patients. Using PACSIN2, RAC1, ITPA genes, along with TPMT and NUDT15, as potential biomarkers for thiopurine-related gastrointestinal toxicity is supported by evidence.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Medicine, Research & Experimental
Ping'an Ding, Pengpeng Liu, Lingjiao Meng, Qun Zhao
Summary: Immune checkpoint inhibitors (ICIs) have shown unprecedented anti-tumor effects in the past decade, greatly improving the prognosis of many malignant tumors. However, immune-related adverse events (irAEs) can occur during immunotherapy, which is a major obstacle to ICI treatment. Accurate identification and screening of sensitive markers of irAE are crucial for successful ICI treatment.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2023)
Article
Computer Science, Artificial Intelligence
Simone Scaboro, Beatrice Portelli, Emmanuele Chersoni, Enrico Santus, Giuseppe Serra
Summary: This paper evaluates 19 Transformer-based models for Adverse Drug Event (ADE) extraction on informal texts and analyzes the relationship between model performance and a set of features.
KNOWLEDGE-BASED SYSTEMS
(2023)
Review
Pediatrics
Alessandra Bosch, Manuela Albisetti
Summary: Venous thromboembolism (VTE) is becoming increasingly significant in pediatric patients. Current standardized anticoagulants have not been comprehensively tested in pediatric patients. Direct oral anticoagulants (DOACs) have shown to be safe and effective in the treatment and secondary prevention of pediatric VTE. This review focuses on adverse events (AEs) of specific DOACs reported in clinical trials in children and compares them to standard care, aiding clinicians in selecting the right anticoagulation for pediatric patients.
FRONTIERS IN PEDIATRICS
(2022)
Article
Cardiac & Cardiovascular Systems
Ninghao Huang, Zhenhuang Zhuang, Zimin Song, Wenxiu Wang, Yueying Li, Yimin Zhao, Wendi Xiao, Xue Dong, Jinzhu Jia, Zhonghua Liu, Caren E. Smith, Tao Huang
Summary: The study constructed a modified Healthy Aging Index (mHAI) to quantify the association between physiological aging and vascular events. The mHAI was found to be significantly correlated with major cardiovascular events, with systolic blood pressure being the most significant factor. A healthy lifestyle was shown to attenuate the associations between mHAI and vascular events.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)